



EUROPEAN
COMMISSION

Brussels, XXX
SCBP41-Doc.xx
[...] (2014) XXX draft

COMMISSION IMPLEMENTING REGULATION (EU) No .../..

of XXX

approving *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A as an active substance for use in biocidal products for product-type 18

(Text with EEA relevance)

COMMISSION IMPLEMENTING REGULATION (EU) No .../..

of **XXX**

approving *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A as an active substance for use in biocidal products for product-type 18

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products¹, and in particular the third subparagraph of Article 89(1) thereof,

Whereas:

- (1) Commission Delegated Regulation (EU) No XX/2014² establishes a list of active substances to be evaluated with a view to their possible approval for use in biocidal products or inclusion into Annex I to Regulation (EU) No 528/2012. That list includes *Bacillus thuringiensis* subsp. *israelensis* serotype H14.
- (2) *Bacillus thuringiensis* subsp. *israelensis* serotype H14 has been evaluated in accordance with Article 90(2) of Regulation (EU) No 528/2012 for use in biocidal products for product-type 18, insecticides, acaricides and products to control other arthropods, as defined in Annex V to Regulation (EU) No 528/2012.
- (3) The data submitted for the purpose of the evaluation allowed conclusions to be drawn only regarding a certain form of *Bacillus thuringiensis* subsp. *israelensis* serotype H14, i.e. *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A. The evaluation did not allow conclusions to be drawn regarding any other substance complying with the definition of *Bacillus thuringiensis* subsp. *israelensis* serotype H14 in the abovementioned list of active substances in Regulation (EU) No XX/2014. Therefore, only *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A should be covered by this approval.
- (4) Italy was designated as evaluating competent authority and submitted an assessment report, together with its recommendations, to the Commission on 12 June 2009 in accordance with paragraphs 4 and 6 of Article 14 of Commission Regulation (EC) No 1451/2007³.

¹ OJ L 167, 27.6.2012, p. 1.

² Commission Delegated Regulation (EU) No XX/2014 of XXXX on the work programme for the systematic examination of all existing active substances contained in biocidal products referred to in Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L XX, XXX, p. X).

³ Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (OJ L 325, 11.12.2007, p. 3).

- (5) The opinion of the European Chemicals Agency was formulated on 19 June 2014 by the Biocidal Product Committee, having regard to the conclusions of the evaluating competent authority.
- (6) According to that opinion, biocidal products used for product-type 18 and containing *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC of the European Parliament and of the Council⁴ provided that certain specifications and conditions relating to its use are satisfied.
- (7) It is therefore appropriate to approve *Bacillus thuringiensis* subsp. *israelensis* serotype H14, strain SA3A for use in biocidal products for product-type 18 subject to compliance with certain specifications and conditions.
- (8) Since the evaluations did not address nanomaterials, the approval should not cover such materials in accordance with Article 4(4) of Regulation (EU) No 528/2012.
- (9) A reasonable period should be allowed to elapse before an active substance is approved, in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
- (10) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS REGULATION:

Article 1

Bacillus thuringiensis subsp. *israelensis* serotype H14, strain SA3A shall be approved as an active substance for use in biocidal products for product-type 18, subject to the specifications and conditions set out in the Annex.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels,

For the Commission
The President

⁴ Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ L 123, 24.4.1998, p. 1).